Galena Biopharma has been highlighted in a Seeking Alpha article for its performance in developing breakthrough oncology treatments for various forms of cancer.
Contributing writer Kingmaker discusses the company’s Folate Binding Protein (FBP) and financial position, as well as provides a technical chart, before concluding that, “Galena Biopharma appears to be one company that deserves at least a small allocation of capital. By building a diversified portfolio of breakthrough treatments and products, corporate management appears to be serious about building a global biotechnology company that can grow significantly during the years to come.”
To read the article in its entirety visit http://seekingalpha.com/article/1857581
Galena is currently conducting a phase 1 FBP trial to prevent endometrial and ovarian cancer recurrences in patients who have already undergone therapy and are disease-free. So far, the company has determined optimal dose and found FBP’s toxicity to be minimal in addition to favorable follow-up.
“Investors should also note the results from the company’s 6-month follow-up. The vaccine group only demonstrated 2 recurrences, a total percentage of 13.3 percent. That compares extremely favorable to the number of recurrences (4) in the control group, which was a 25 percent rate,” writes Kingmaker.
For the third quarter of 2013, Galena reported an improvement of approximately $56.8 million in cash, cash equivalents and short-term investments, as compared to previous quarters. The article recaps the company’s financial performance and notes upcoming potential.
“As investors soak in the promising early results from the FBP Phase 1 trial, they should also be aware that Galena continues to push forward with NeuVax (used in the treatment of breast cancer). The company expects to complete the NeuVax Phase 3 enrollment early next year. Galena also expects to announce interim results based upon 70 events by the summer of 2014 at the very latest. If positive, these interim results will likely send the shares to new 52-week highs. In fact, biotech companies typically see significant share price runs over the course of a Phase 3 trial, up until the results are announced. If investors have a reason to believe the results will be positive, Galena could end up being the biotech stock of 2014,” writes Kingmaker.
For more information, visit www.galenabiopharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
